A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
about
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in CancerUtilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy DeliveryInteractions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and CancerConcise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic TargetSubgroup-specific alternative splicing in medulloblastomaAnti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cellsA unified model of the hierarchical and stochastic theories of gastric cancer.From General Aberrant Alternative Splicing in Cancers and Its Therapeutic Application to the Discovery of an Oncogenic DMTF1 Isoform.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaCD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition.The translational significance of epithelial-mesenchymal transition in head and neck cancer.Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosomeGermline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma.Hyaluronan-CD44 interactions as potential targets for cancer therapy.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics.Antibody Drug Conjugates: Nonclinical Safety Considerations.Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivoThe melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma.Isolation of All CD44 Transcripts in Human Epidermis and Regulation of Their Expression by Various Agents.LRP-1--CD44, a new cell surface complex regulating tumor cell adhesion.Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumorsPhototheranostics of CD44-positive cell populations in triple negative breast cancer.Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies.Investigational antibody-drug conjugates for hematological malignancies.CD44 in hematological neoplasias.PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.Targeted therapy in head and neck cancer.Pharmacokinetic considerations for antibody drug conjugates.Role of CD44 in tumour progression and strategies for targeting.Optimising the delivery of tubulin targeting agents through antibody conjugation.Antibody therapy for acute myeloid leukaemia.Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498.Metastasis review: from bench to bedside.Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer.Perspectives of CD44 targeting therapies.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
P2860
Q26744088-4025A084-060D-4B48-AD6E-60C84489073FQ26747319-B7680B19-6B30-4F50-A2C7-357A0647476DQ26786070-C3F0A391-8A27-4BC2-B347-1D54F267F234Q27021261-9474B83F-8AF4-4DFC-985C-5C848565BFFEQ28083115-B465CBC1-630E-469B-B860-CFBA31175575Q28260516-44E5AFBD-7B7E-43BB-B7A0-6F08765C3CDEQ28732763-AA90C2EF-D4F9-4826-A281-7AA81F5002CEQ33577624-E6441D64-739D-46DE-B33F-638F962E695CQ34048030-050F5C6E-953A-435C-9105-9C353120DEC0Q34181954-3DCB45F9-8C29-42BA-B2E1-988E276E954DQ34600387-C42BCE9C-2F0F-4AFE-8D54-456663B242D7Q34996810-BA2F1AFC-B374-4A8C-B740-46E86A7B5259Q35023463-13575908-485F-434A-AF3D-87B635656027Q35114557-CA5ED467-847D-4DC3-B04B-FB5A44489F47Q35194441-A80F03DA-860D-4E33-ADDD-75804517695EQ35459059-68965D62-838C-48D8-B6AC-4AD32E2E26A1Q35585820-3E5AF116-0DC8-4D42-9C36-E42A7B541C99Q35967917-6D3ADF78-829A-4AF8-BFC7-D9937475BC63Q36021000-95753927-B600-4B08-A937-8EE005B1056DQ36097890-A67CA807-653C-4085-8AAE-F75CF93686C1Q36098905-CD5CD0EE-57B5-44C8-B798-15460AD4BE50Q36211012-4E8D0CF8-53C7-4273-A80F-3643C32ED88BQ36879421-C16E960D-6DAD-4696-A316-A0235CCE8191Q37006182-A929B968-661D-417A-BC69-A3F88A823578Q37188974-701E12E9-D670-46A7-82C2-C34A105740CBQ37666618-2404D4CD-A18B-46F2-8F65-171CDFBADCB5Q37698959-17F3CD0F-42E1-452C-85E2-48C2217ED6B7Q37818256-0E9E7961-F387-46E5-AC56-896F9E6F7024Q37831812-DCFF4D93-C381-4ACF-BFB7-92D0FDE8184AQ37978157-5AC03D09-18AF-4722-956C-CFA883F0FD77Q37988981-FBC31BDA-E053-4EA8-9C30-9391935DE726Q38022192-A4C8B0A1-C51A-4387-BDCC-3DC6C79EB0E3Q38023546-AFF27548-A4DB-44A8-AF5B-9E1031C5AA87Q38024991-CFC91358-E82A-466F-9666-BC8C02261CF6Q38169814-A8E3785C-7BAF-4203-9C30-3D52B26AFEA0Q38209572-D7B8BACD-3CE3-49F7-8A9E-07F6EFFC97B6Q38237985-D60AE583-5F20-4296-9C89-B32E56F7DB5DQ38281132-502F91FD-01F0-4C2B-A932-6480BE430D24Q38282790-9111A924-180E-4375-9731-F4070A4B7F2CQ38289029-F19E589C-9088-4B2C-8613-38C05B7B0BD9
P2860
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A phase I dose escalation stud ...... the head and neck or esophagus
@ast
A phase I dose escalation stud ...... the head and neck or esophagus
@en
A phase I dose escalation stud ...... the head and neck or esophagus
@nl
type
label
A phase I dose escalation stud ...... the head and neck or esophagus
@ast
A phase I dose escalation stud ...... the head and neck or esophagus
@en
A phase I dose escalation stud ...... the head and neck or esophagus
@nl
prefLabel
A phase I dose escalation stud ...... the head and neck or esophagus
@ast
A phase I dose escalation stud ...... the head and neck or esophagus
@en
A phase I dose escalation stud ...... the head and neck or esophagus
@nl
P2093
P3181
P1476
A phase I dose escalation stud ...... the head and neck or esophagus
@en
P2093
Alexander Staab
Bernard M Tijink
C René Leemans
Giuseppe Giaccone
Guus A M S van Dongen
Margreet S Lang
Remco de Bree
P304
P3181
P356
10.1158/1078-0432.CCR-06-0910
P407
P433
P577
2006-10-15T00:00:00Z